# 510 (k) Summary

This summary of $5 1 0 ( k )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: k130945

Submitter's name, address, telephone, contact person, and the date the summary was prepared:

Submitter's Name: Submitter's Address:

Eurospital S.p.A.   
Via Flavia, 122   
34147 Trieste   
Italy   
Tel. $+ 3 9$ 0408997269   
Dr. Claudio G. Frattini, Technical Director February 29, 2013

Submitter's Telephone Number: Submitter's Contact Name: Date of 510(k) Preparation:

Name of the device, including the trade or proprietary name, the common or usual name and the classification name:

Proprietary Name: Common Name:

CALPREST Fecal calprotectin immunological test system

Classification Name:

Calprotectin, Fecal; 21 CFR 866.5180; Class II   
Product Code: NXO

Identification of the legally marketed device to which the submitter claims substantialequivalence:

Predicate Device Name:

PhiCalTM Test   
510(k) Number: K050007   
Regulation Number: 21CFR866.5180   
Regulation Class: Class II   
Distributed By: Genova Diagnostics   
Ashville, NC

# Description of the device

Calprest® is an enzyme-linked immunosorbent assay (ELISA) system with colorimetric detection based on the uof polyclonal antibody against calprotectn.Calprotectn present in the diluted sample is bound by the any asorbeto the suracf he plastic welThe nzyme conjgat antoy bins  the cap antigen and subsequently the enzyme catalyzes the conversion of the substrate to a colored product.The y e o prooralemnt  njugaou  thushemontpurd calprotectin.Concentration of calprotectin in the samples is calculated using the provided standards.

5. Statement of the intended use of the device

# Device Intended Use:

Calprest® is a quantitative ELISA for detecting concentration of faecal calprotectin. Calprest® can be used as an in vitro diagnostic to aid in the diagnosis of Inflammatory Bowel Diseases (IBD, Crohn's disease and ulcerative colitis) and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and laboratory findings.

# 6.Summary of the technological characteristics of the device

Calprest $\textcircled{7}$ s entical to PhiCaTest in that they are manufacured by Eurospital S... Triese, Italy.Th l the assay.

# 7. Summary of performance characteristics

# 7.1 Expected Values

<table><tr><td rowspan=1 colspan=1>Calprotectin Concentration</td><td rowspan=1 colspan=1>Interpretation</td><td rowspan=1 colspan=1>Follow-Up</td></tr><tr><td rowspan=1 colspan=1>&lt;15.6 - 50 mg/kg</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>None</td></tr><tr><td rowspan=1 colspan=1>50 - 120 mg/kg</td><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>Re-evaluate at 4-6 weeks</td></tr><tr><td rowspan=1 colspan=1>&gt;120 mg/kg</td><td rowspan=1 colspan=1>Abnormal</td><td rowspan=1 colspan=1>Repeat as clinically indicated</td></tr></table>

# 7.2 Clinical Performance

<table><tr><td rowspan=2 colspan=2>Borderline consideredPositive   Tes           .x</td><td rowspan=1 colspan=2>IBD          :</td><td rowspan=2 colspan=1>Total .$-..</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>Calprest</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>101</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>37</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>138</td></tr><tr><td rowspan=1 colspan=2>Sensitivity</td><td rowspan=1 colspan=1>96.9%</td><td rowspan=1 colspan=2>(95%CI 91.3% - 99.4%)</td></tr><tr><td rowspan=1 colspan=2>Specificity</td><td rowspan=1 colspan=1>85.0%</td><td rowspan=1 colspan=2>(95%CI 70.2% - 94.3%)</td></tr><tr><td rowspan=1 colspan=2>PPV*</td><td rowspan=1 colspan=1>94.1%</td><td rowspan=1 colspan=2>(95% CI 87.5% - 97.8%)</td></tr><tr><td rowspan=1 colspan=2>NPV**</td><td rowspan=1 colspan=1>91.9%</td><td rowspan=1 colspan=2>(95% CI 78.1% - 98.3%)</td></tr></table>

<table><tr><td rowspan=2 colspan=2>Borderline consideredrNegative                  .:</td><td rowspan=1 colspan=2>$\frac{ { 2 }$a}$  3     IBD</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>.Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>Calprest</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>81</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>57</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>138</td></tr><tr><td rowspan=1 colspan=2>Sensitivity</td><td rowspan=1 colspan=1>79.6%</td><td rowspan=1 colspan=2>(95%CI 70.3% - 87.1%)$</td></tr><tr><td rowspan=1 colspan=2>Specificity</td><td rowspan=1 colspan=1>92.5%</td><td rowspan=1 colspan=2>(95%CI 79.6% - 98.4%)</td></tr><tr><td rowspan=1 colspan=2>PPV*</td><td rowspan=1 colspan=1>96.3%</td><td rowspan=1 colspan=2>(95%CI 89.6% - 99.2%)</td></tr><tr><td rowspan=1 colspan=2>NPV**</td><td rowspan=1 colspan=1>64.9%</td><td rowspan=1 colspan=2>(95% CI 51.1% - 77.1%)</td></tr></table>

\* PPV: Positive Predictive Value $* *$ NPV: Negative Predictive Value § CI: Confidence Interval

# 7.3 Extraction Reproducibility

Values are reported in mg/kg   

<table><tr><td rowspan=1 colspan=1>Extracted stool sampleNo.</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/kg)</td><td rowspan=1 colspan=1>28.4</td><td rowspan=1 colspan=1>41.1</td><td rowspan=1 colspan=1>79.4</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>13.6</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>7.0</td></tr></table>

# 7.4 Comparison

# 7.4.1 Device Comparison

Reagents: Calprest®, code 9031 manufactured by Eurospital S.p.A.   
Predicate device: PhiCal Test - FDA 510(k) - K050007 manufactured by Eurospital S.p.A.

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New device</td><td colspan="1" rowspan="1">Predicate (K050007)</td></tr><tr><td colspan="1" rowspan="1">Y</td><td colspan="1" rowspan="1">Calprest®, code 9031</td><td colspan="1" rowspan="1">PhiCal Test code 9053</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">to aid in the diagnosis of InflammatoryBowel Diseases (IBD, Crohn'sdisease and ulcerative colitis) and todifferentiate IBD from Irritable BowelSyndrome (IBS) in conjunction withother clinical and laboratory findings.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">ELISA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antigen</td><td colspan="1" rowspan="1">Calprotectin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay format</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Positive and Negative controls</td><td colspan="1" rowspan="1">Ready to use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">stool</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample dilution</td><td colspan="1" rowspan="1">1:2500</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Incubation time</td><td colspan="1" rowspan="1">45-45-30 minutes at RT</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample volume</td><td colspan="1" rowspan="1">1-5 g stool</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Extraction solution</td><td colspan="1" rowspan="1">2,5x concentrate</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample buffer diluent</td><td colspan="1" rowspan="1">10x concentrate</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Wash buffer</td><td colspan="1" rowspan="1">20x concentrate</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">Alkaline phosphatase</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Substrate</td><td colspan="1" rowspan="1">pNPP</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Platform</td><td colspan="1" rowspan="1">96 well microtiter plate</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">OD Reading</td><td colspan="1" rowspan="1">405 nm</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Cut-off</td><td colspan="1" rowspan="1">50 mg/kg (μg/g)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New device.</td><td colspan="1" rowspan="1">Predicate (K050007)</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Calprest®, code 9031</td><td colspan="1" rowspan="1">PhiCal Test, code 9053</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">6 levels:6.25, 12.5, 25, 50, 100, 200 ng/ml</td><td colspan="1" rowspan="1">5 levels:6.5, 12.5, 25, 50, 100 ng/ml</td></tr></table>

# 7.4.2 Method Comparison

<table><tr><td colspan="4">Borderline Value considered as Positive α Y 2.3</td></tr><tr><td>$a. A $\frac{ { }$ : : L</td><td colspan="4">PhiCalTM</td></tr><tr><td rowspan="4" colspan="2">Pos Calprest® ® Neg 94.9%</td><td>Pos</td><td>Neg</td><td rowspan="4">75 56</td></tr><tr><td>74</td><td>1</td></tr><tr><td>4</td><td>52 53</td></tr><tr><td colspan="2">78</td></tr><tr><td colspan="2" rowspan="2">Positive Agreement Negative Agreement Overall agreement</td><td colspan="2">(95% C.I. 87.4% - 98.6%)</td></tr><tr><td colspan="2">(95% C.I. 89.9% - 100.0%) (95% C.I. 91.3% - 98.7%)</td></tr></table>

<table><tr><td colspan="3">Borderline Value considered as Negative</td><td colspan="2">*</td></tr><tr><td></td><td colspan="5">PhiCalTM</td></tr><tr><td rowspan="4" colspan="2">Pos Calprest® ® Neg</td><td>Pos</td><td colspan="2">Neg</td><td rowspan="4">45 86</td></tr><tr><td>43</td><td>2</td><td></td></tr><tr><td rowspan="2">4</td><td></td><td>82</td></tr><tr><td>47</td><td>84</td></tr><tr><td>Positive Agreement Negative Agreement</td><td>91.5% 97.6%</td><td colspan="3">(95% C.I. 79.6% - 97.6%) (95% C.I. 91.7% - 99.7%)</td></tr></table>

Deming Regression Analysis (y: Calprest, x: PhiCal):   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>Y-intercept (95% Cl)</td></tr><tr><td rowspan=1 colspan=1>y=0.98x-1.85</td><td rowspan=1 colspan=1>0.98(0.96 to 1.01)</td><td rowspan=1 colspan=1>-1.85 (-3.96 to 0.96)</td></tr></table>

# 7.5 Intra-assay Precision

Values are reported in mg/kg

<table><tr><td rowspan=1 colspan=1>Extracted stoolsample No.</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/kg)</td><td rowspan=1 colspan=1>438.7</td><td rowspan=1 colspan=1>355.2</td><td rowspan=1 colspan=1>352.9</td><td rowspan=1 colspan=1>311.7</td><td rowspan=1 colspan=1>199.9</td><td rowspan=1 colspan=1>125.7</td><td rowspan=1 colspan=1>57.8</td><td rowspan=1 colspan=1>27.7</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>33.7</td><td rowspan=1 colspan=1>43.0</td><td rowspan=1 colspan=1>43.7</td><td rowspan=1 colspan=1>38.8</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>% CV .</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>3.7</td></tr></table>

# 7.6 Inter-assay Precision

Values are reported in mg/kg   

<table><tr><td rowspan=1 colspan=1>Extracted stoolsample No.</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/kg)</td><td rowspan=1 colspan=1>359.9</td><td rowspan=1 colspan=1>209.8</td><td rowspan=1 colspan=1>185.5</td><td rowspan=1 colspan=1>117.0</td><td rowspan=1 colspan=1>70.4</td><td rowspan=1 colspan=1>48.8</td><td rowspan=1 colspan=1>40.9</td><td rowspan=1 colspan=1>20.6</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>27.5</td><td rowspan=1 colspan=1>17.8</td><td rowspan=1 colspan=1>17.8</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>12.4</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Lot # 5637</td><td rowspan=1 colspan=2>Lot # 5888</td><td rowspan=1 colspan=2>Lot # 5488</td><td rowspan=1 colspan=3>Overall</td></tr><tr><td rowspan=1 colspan=1>Extracted stoolsample No</td><td rowspan=1 colspan=1>Mean(mg/kg)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Mean(mg/kg)</td><td rowspan=1 colspan=1>%CV.</td><td rowspan=1 colspan=1>Mean(mg/kg)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Mean(mg/kg)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>106.1</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>103.2</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>113.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>107.7</td><td rowspan=1 colspan=1>5.779</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>63.4</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>60.4</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>65.5</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>63.1</td><td rowspan=1 colspan=1>3.682</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>185.0</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>177.7</td><td rowspan=1 colspan=1>13.3</td><td rowspan=1 colspan=1>192.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>185.1</td><td rowspan=1 colspan=1>14.545</td><td rowspan=1 colspan=1>7.9</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>44.0</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>43.5</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>43.8</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>43.8</td><td rowspan=1 colspan=1>1.358</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>36.5</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>38.2</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>33.2</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>36.0</td><td rowspan=1 colspan=1>3.001</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>354.6</td><td rowspan=1 colspan=1>13.6</td><td rowspan=1 colspan=1>340.2</td><td rowspan=1 colspan=1>13.7</td><td rowspan=1 colspan=1>340.0</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>344.9</td><td rowspan=1 colspan=1>42.615</td><td rowspan=1 colspan=1>12.4</td></tr></table>

# 7.8 Site-to-site precision

<table><tr><td></td><td>Sample# Actual value mg/kg</td><td>Site 1 mg/kg Site 2 mg/kg Site 3 mg/kg</td><td></td><td>Mean (mg/kg) St. Dev.</td><td>CV%</td><td>Delta %</td></tr><tr><td>G52</td><td>28.0</td><td>27.7 33.3</td><td>28.2</td><td>29.7 3.094</td><td>10.4%</td><td>106%</td></tr><tr><td>G44</td><td>66.0</td><td>74.1 66.7</td><td>69.4</td><td>70.1 3.770</td><td>5.4%</td><td>106%</td></tr><tr><td>G11</td><td>101.0</td><td>102.1 99.9</td><td>106.2</td><td>102.7 3.210</td><td>3.1%</td><td>102%</td></tr><tr><td>G04</td><td>160.0</td><td>157.6 169.2</td><td>161.1</td><td>162.6 5.982</td><td>3.7%</td><td>102%</td></tr><tr><td>G16</td><td>349.0</td><td>332.8 356.0</td><td>326.1</td><td>338.3 15.659</td><td>4.6%</td><td>97%</td></tr><tr><td>G54</td><td>557.0</td><td>510.8 565.6</td><td>550.4</td><td>542.2 28.255</td><td>5.2%</td><td>97%</td></tr></table>

# 7.9 Linearity

# 7.9.1 Matrix Linearity

![](images/241d8dd1869ec0ca19bbfcbd4ec129ad906958b00d8282a2aa456d9fa375bccd.jpg)

<table><tr><td rowspan=1 colspan=1>PoolNo.</td><td rowspan=1 colspan=1>Test Range(μg/g)</td><td rowspan=1 colspan=1>Slope(95% Cl)</td><td rowspan=1 colspan=1>Y-intercept(95% CI)</td><td rowspan=1 colspan=1>R2</td><td rowspan=1 colspan=1>% Recovery Rate(Obtained/Theoretical)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>20.4 to 492.8</td><td rowspan=1 colspan=1>1.0126(0.9461 to 1.079)</td><td rowspan=1 colspan=1>~3.777(-23.85 to 16.29)</td><td rowspan=1 colspan=1>0.9946</td><td rowspan=1 colspan=1>87.0% to 113.2%</td></tr></table>

![](images/95816e5e06bbf4e5fbd2564fdf395edfb8add9ee290508055d4b588012e42796.jpg)

<table><tr><td rowspan=1 colspan=1>SampleNo.</td><td rowspan=1 colspan=1>Test Range(μg/g)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Y-intercept(95% CI)</td><td rowspan=1 colspan=1>$R^{}$•</td><td rowspan=1 colspan=1>% Recovery Rate(Obtained/Theoretical)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8.2 to 538.5</td><td rowspan=1 colspan=1>0.9853(0.9498 to 1.0208)</td><td rowspan=1 colspan=1>-2.7140(-5.813 to 11.241)</td><td rowspan=1 colspan=1>0.9990</td><td rowspan=1 colspan=1>95.2% to 109.3%</td></tr></table>

# 7.10 Calprotectin Recovery

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=8>Calprotectin Recovery Data                                                                 .</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Description</td><td rowspan=1 colspan=1>#1</td><td rowspan=1 colspan=1>#2</td><td rowspan=1 colspan=1>#3</td><td rowspan=1 colspan=1>#4</td><td rowspan=1 colspan=1>#5</td><td rowspan=1 colspan=1>#6</td><td rowspan=1 colspan=1>#7</td></tr><tr><td rowspan=1 colspan=1>(a)</td><td rowspan=1 colspan=1>Baseline (mg/kg)</td><td rowspan=1 colspan=1>18.3</td><td rowspan=1 colspan=1>47.5</td><td rowspan=1 colspan=1>59.4</td><td rowspan=1 colspan=1>66.5</td><td rowspan=1 colspan=1>115.2</td><td rowspan=1 colspan=1>232.5</td><td rowspan=1 colspan=1>.421.9</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Spike Value (mg/kg)</td><td rowspan=1 colspan=1>31.2</td><td rowspan=1 colspan=1>31.2</td><td rowspan=1 colspan=1>31.2</td><td rowspan=1 colspan=1>31.2</td><td rowspan=1 colspan=1>31.2</td><td rowspan=1 colspan=1>31.2</td><td rowspan=1 colspan=1>31.2</td></tr><tr><td rowspan=1 colspan=1>(b)</td><td rowspan=1 colspan=1>Theoretical(Base + Spike) (mg/kg)</td><td rowspan=1 colspan=1>49.6</td><td rowspan=1 colspan=1>78.8</td><td rowspan=1 colspan=1>90.6</td><td rowspan=1 colspan=1>97.8</td><td rowspan=1 colspan=1>146.6</td><td rowspan=1 colspan=1>263.7</td><td rowspan=1 colspan=1>452.1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Observed(Base + Spike) (mg/kg)</td><td rowspan=1 colspan=1>49.8</td><td rowspan=1 colspan=1>81.1</td><td rowspan=1 colspan=1>100.1</td><td rowspan=1 colspan=1>108.7</td><td rowspan=1 colspan=1>166.0</td><td rowspan=1 colspan=1>271.3</td><td rowspan=1 colspan=1>475.0</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>% Recovery</td><td rowspan=1 colspan=1>100.5</td><td rowspan=1 colspan=1>103.0</td><td rowspan=1 colspan=1>110.5</td><td rowspan=1 colspan=1>111.1</td><td rowspan=1 colspan=1>113.4</td><td rowspan=1 colspan=1>102.8</td><td rowspan=1 colspan=1>112.6</td></tr></table>

# 7.11 LoB and LoD

LoB = 3.04 mg/kg $\mathsf { L o D } = 3 . 9 8 ~ \mathsf { m g / k g }$

# 7.12 Interfering Substance

A number of potential interfering foods, pharmaceutical and nutraceutical substances were tested.   
No interferences were observed.

<table><tr><td rowspan=2 colspan=1>Pool</td><td rowspan=2 colspan=1>No additionmg/kg</td><td rowspan=2 colspan=10>Addition of bacterial suspensions - Table 1E coli          Salmonella spp Shigella spp Yesinia spp  Klebsiella sppmg/kg   Δ% mg/kg   Δ% mg/kg Δ% mg/kg   Δ% mg/kg  Δ%</td></tr><tr><td rowspan=1 colspan=2> Shigella sppmg/kg Δ%</td><td rowspan=1 colspan=1>Yesinia sppmg/kg</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>459.3</td><td rowspan=1 colspan=1>470.8</td><td rowspan=1 colspan=1>102.5</td><td rowspan=1 colspan=1>447.9</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>466.7</td><td rowspan=1 colspan=1>101.6</td><td rowspan=1 colspan=1>441.9</td><td rowspan=1 colspan=1>96.2</td><td rowspan=1 colspan=1>455.5</td><td rowspan=1 colspan=1>99.2</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>273.2</td><td rowspan=1 colspan=1>262.1</td><td rowspan=1 colspan=1>95.9</td><td rowspan=1 colspan=1>297.8</td><td rowspan=1 colspan=1>109.0</td><td rowspan=1 colspan=1>261.4</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>280.8</td><td rowspan=1 colspan=1>102.8</td><td rowspan=1 colspan=1>261.1</td><td rowspan=1 colspan=1>95.6</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>143.6</td><td rowspan=1 colspan=1>137.1</td><td rowspan=1 colspan=1>95.5</td><td rowspan=1 colspan=1>146.4</td><td rowspan=1 colspan=1>102.0</td><td rowspan=1 colspan=1>148.1</td><td rowspan=1 colspan=1>103.1</td><td rowspan=1 colspan=1>136.8</td><td rowspan=1 colspan=1>95.3</td><td rowspan=1 colspan=1>150.5</td><td rowspan=1 colspan=1>104.8</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>68.2</td><td rowspan=1 colspan=1>66.3</td><td rowspan=1 colspan=1>97.2</td><td rowspan=1 colspan=1>68.0</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>69.7</td><td rowspan=1 colspan=1>102.2</td><td rowspan=1 colspan=1>65.0</td><td rowspan=1 colspan=1>95.3</td><td rowspan=1 colspan=1>70.5</td><td rowspan=1 colspan=1>103.4</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>30.1</td><td rowspan=1 colspan=1>31.2</td><td rowspan=1 colspan=1>103.8</td><td rowspan=1 colspan=1>29.7</td><td rowspan=1 colspan=1>98.7</td><td rowspan=1 colspan=1>31.6</td><td rowspan=1 colspan=1>105.1</td><td rowspan=1 colspan=1>30.2</td><td rowspan=1 colspan=1>100.4</td><td rowspan=1 colspan=1>31.2</td><td rowspan=1 colspan=1>103.6</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Pool</td><td rowspan=2 colspan=1>No additionmg/kg</td><td rowspan=2 colspan=10>Addition of Drugs, Nutrients and Hemoglobin - Table 2aVancomycin Ciproflaxin hclVitamin E      Prevacid      Azathioprinemg/kg  Δ% mg/kg   ∆% mg/kg 0% mg/kg  Δ% mg/kg  Δ%</td></tr><tr><td rowspan=1 colspan=2>Vitamin Emg/kg 0%</td><td rowspan=1 colspan=1>Prevacidmg/kg</td><td rowspan=1 colspan=1>Δ%</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>468,9</td><td rowspan=1 colspan=1>467,1  .</td><td rowspan=1 colspan=1>99,6</td><td rowspan=1 colspan=1>479,4</td><td rowspan=1 colspan=1>102,2</td><td rowspan=1 colspan=1>457,9</td><td rowspan=1 colspan=1>97.7</td><td rowspan=1 colspan=1>453,5</td><td rowspan=1 colspan=1>96,7</td><td rowspan=1 colspan=1>468,4</td><td rowspan=1 colspan=1>99,9</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>268,1</td><td rowspan=1 colspan=1>272,9</td><td rowspan=1 colspan=1>101,8</td><td rowspan=1 colspan=1>270.9</td><td rowspan=1 colspan=1>101,0</td><td rowspan=1 colspan=1>261,0</td><td rowspan=1 colspan=1>97,4</td><td rowspan=1 colspan=1>271,2</td><td rowspan=1 colspan=1>101,2</td><td rowspan=1 colspan=1>263,4</td><td rowspan=1 colspan=1>98.2</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>145.4</td><td rowspan=1 colspan=1>141,7</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>140,5</td><td rowspan=1 colspan=1>96,6</td><td rowspan=1 colspan=1>140,0</td><td rowspan=1 colspan=1>96,3</td><td rowspan=1 colspan=1>144,2</td><td rowspan=1 colspan=1>99.2</td><td rowspan=1 colspan=1>143,4</td><td rowspan=1 colspan=1>98,6</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>68.8</td><td rowspan=1 colspan=1>69,1</td><td rowspan=1 colspan=1>100,4</td><td rowspan=1 colspan=1>69,2</td><td rowspan=1 colspan=1>100,6</td><td rowspan=1 colspan=1>68,8</td><td rowspan=1 colspan=1>100,0</td><td rowspan=1 colspan=1>68.2</td><td rowspan=1 colspan=1>99.1</td><td rowspan=1 colspan=1>68.5</td><td rowspan=1 colspan=1>99.6</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>31,2</td><td rowspan=1 colspan=1>32.1</td><td rowspan=1 colspan=1>97.2</td><td rowspan=1 colspan=1>32,7</td><td rowspan=1 colspan=1>104 8</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>32,6</td><td rowspan=1 colspan=1>104.5</td><td rowspan=1 colspan=1>32,5</td><td rowspan=1 colspan=1>104,2</td></tr></table>

<table><tr><td rowspan=3 colspan=1>Pool</td><td rowspan=3 colspan=1>No additionmg/kg</td><td rowspan=3 colspan=10>Addition of Drugs, Nutrients and Hemoglobin - Table 2aPentasa       Asacol          Prednisone   Multivitamin  Hemoglobinmg/kg  ∆% mg/kg   Δ% mg/kg  Δ% mg/kg   Δ%  mg/kg  Δ%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Prednisone</td><td rowspan=1 colspan=1></td><td rowspan=2 colspan=2>Multivitaminmg/kg   Δ%</td><td rowspan=2 colspan=1>Hemoglobinmg/kg</td></tr><tr><td rowspan=1 colspan=1>∆%</td><td rowspan=1 colspan=1>mg/kg</td><td rowspan=1 colspan=1>Δ%</td><td rowspan=1 colspan=1>mg/kg</td><td rowspan=1 colspan=1>Δ%</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>468.9</td><td rowspan=1 colspan=1>461,8</td><td rowspan=1 colspan=1>98,5</td><td rowspan=1 colspan=1>461,5</td><td rowspan=1 colspan=1>98,4</td><td rowspan=1 colspan=1>446.7</td><td rowspan=1 colspan=1>95.3</td><td rowspan=1 colspan=1>478,4</td><td rowspan=1 colspan=1>102.0</td><td rowspan=1 colspan=1>102,0473.3</td><td rowspan=1 colspan=1>100,9</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>268.1</td><td rowspan=1 colspan=1>271,1</td><td rowspan=1 colspan=1>101,1</td><td rowspan=1 colspan=1>273,5</td><td rowspan=1 colspan=1>102,0</td><td rowspan=1 colspan=1>268,6</td><td rowspan=1 colspan=1>100,2</td><td rowspan=1 colspan=1>272,2</td><td rowspan=1 colspan=1>101,5</td><td rowspan=1 colspan=1>274,7</td><td rowspan=1 colspan=1>102,5</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>145,4</td><td rowspan=1 colspan=1>150,1</td><td rowspan=1 colspan=1>103,2</td><td rowspan=1 colspan=1>138,2</td><td rowspan=1 colspan=1>95,0</td><td rowspan=1 colspan=1>138,5</td><td rowspan=1 colspan=1>95.3</td><td rowspan=1 colspan=1>146.0</td><td rowspan=1 colspan=1>100,4</td><td rowspan=1 colspan=1>146,6</td><td rowspan=1 colspan=1>100.8</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>68.8</td><td rowspan=1 colspan=1>70.7</td><td rowspan=1 colspan=1>102,8</td><td rowspan=1 colspan=1>71,0</td><td rowspan=1 colspan=1>103,2</td><td rowspan=1 colspan=1>71,1</td><td rowspan=1 colspan=1>103,3</td><td rowspan=1 colspan=1>69.2</td><td rowspan=1 colspan=1>100.6</td><td rowspan=1 colspan=1>69,6</td><td rowspan=1 colspan=1>101,2</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>31,2</td><td rowspan=1 colspan=1>32,2</td><td rowspan=1 colspan=1>103.2</td><td rowspan=1 colspan=1>31.8</td><td rowspan=1 colspan=1>99.1</td><td rowspan=1 colspan=1>32,2</td><td rowspan=1 colspan=1>103.2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>98,4</td><td rowspan=1 colspan=1>31,0</td><td rowspan=1 colspan=1>99.4</td></tr></table>

# Food and Drug Administration 10903 New Hampshire Avenue Document Control Center  WO66-G609 Sitver Spring, MD 20993-0002

January 16, 2014

EUROSPITAL S.P.A. c/o MR. DAVID DUNN CONSULTANT 3331 EAGLE WATCH DRIVE WOODSTOCK, GA 30189

Re: K130945 Trade/Device Name: CALPREST® Regulation Number: 21 CFR 866.5180 Regulation Name: Fecal calprotectin immunological test system Regulatory Class: II Product Code: NXO Dated: December 11, 2013 Received: December 12, 2013

Dear Mr. Dunn:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer   
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Leonthenington-S for Maria M. Chan, Ph.D. Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

# Enclosure

<table><tr><td></td><td>DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use</td><td>Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement on last page.</td></tr><tr><td>510(k) Number (if known) K130945</td><td></td><td></td></tr><tr><td>Device Name Calprest</td><td></td><td></td></tr></table>

Indications for Use (Describe)

CativCt IBD from Irritable Bowel Syndrome BS) in conjunction with other clinical and other aboratory findngs.

Type of Use (Select one or both, as applicable) Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED. :1: FOR FDA USE ONLY :   
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)   
Leonthena arrington -S

Page 1ofi